Latest news

Thumbnail image for Celgene pulls plug on Crohn’s disease trials

Celgene pulls plug on Crohn’s disease trials

Celgene is abandoning late-stage testing of its experimental drug mongersen for Crohn’s disease after a Data Monitoring Committee concluded that it would be futile to continue.

20th October 2017

Thumbnail image for NICE no for Opdivo in urothelial carcinoma

NICE no for Opdivo in urothelial carcinoma

The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).

20th October 2017

Thumbnail image for Speedy review for AZ’ Lynparza in breast cancer

Speedy review for AZ’ Lynparza in breast cancer

AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.

19th October 2017

Thumbnail image for US approves second CAR-T therapy

US approves second CAR-T therapy

Gilead’s Yescarta - recently acquired through its purchase of Kite Pharma - has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.

19th October 2017

Thumbnail image for GP referrals to Weight Watchers cut diabetes risk

GP referrals to Weight Watchers cut diabetes risk

More than one third of patients referred by GPs to Weight Watchers in a bid to stave off diabetes saw their blood sugar levels return to normal, a study published in the British Medical Journal has found.

18th October 2017

Thumbnail image for New analysis backs use of Takeda’s Entyvio

New analysis backs use of Takeda’s Entyvio

Takeda has presented data from a post-hoc analysis showing signs of early symptomatic improvement in patients with ulcerative colitis or Crohn’s disease taking Entyvio.

18th October 2017

Thumbnail image for PRIME status for Ignyta’s entrectinib

PRIME status for Ignyta’s entrectinib

European regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval.

18th October 2017

Thumbnail image for ‘No-deal’ Brexit could cost NHS £500m a year

‘No-deal’ Brexit could cost NHS £500m a year

A ‘no-deal’ Brexit that ends healthcare arrangements between the UK and the EU could end up costing the NHS as much as £500 million a year, warns a new paper published by the Brexit Healthcare Alliance, on the back of an analysis by the Nuffield Trust.

17th October 2017

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download